---
title: "Protagonist 治疗公司因可能与强生达成交易的报道而股价大涨"
description: "Protagonist Therapeutics 的股价上涨 9.4%，至 73.34 美元，此前《华尔街日报》报道强生正在洽谈收购该公司。根据最近的收盘价 67.04 美元，Protagonist 的市值超过 40 亿美元。然而，交易并未得到保证，具体细节仍未披露"
type: "news"
locale: "zh-CN"
url: "https://longbridge.com/zh-CN/news/260667559.md"
published_at: "2025-10-10T15:52:01.000Z"
---

# Protagonist 治疗公司因可能与强生达成交易的报道而股价大涨

> Protagonist Therapeutics 的股价上涨 9.4%，至 73.34 美元，此前《华尔街日报》报道强生正在洽谈收购该公司。根据最近的收盘价 67.04 美元，Protagonist 的市值超过 40 亿美元。然而，交易并未得到保证，具体细节仍未披露

By Colin Kellaher

Shares of Protagonist Therapeutics moved higher after The Wall Street Journal reported that Johnson & Johnson is in talks to buy company, citing people familiar with the matter.

Protagonist shares were recently up 9.4%, to $73.34.

A deal isn't guaranteed, and the details being discussed couldn't be learned, the people said, the Journal reported.

Protagonist sports a market capitalization topping $4 billion based on Thursday's closing price of $67.04 for the Newark, Calif., clinical-stage biopharmaceutical company.

Write to Colin Kellaher at colin.kellaher@wsj.com

(END) Dow Jones Newswires

10-10-25 1147ET

### Related Stocks

- [JNJ.US - 强生](https://longbridge.com/zh-CN/quote/JNJ.US.md)
- [PTGX.US - Protagonist治疗](https://longbridge.com/zh-CN/quote/PTGX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Key facts: J&J liable for cancer in talc case; $30M lawsuit filed against lenders | A Pennsylvania jury found Johnson & Johnson liable for cancer linked to its talc baby powder, awarding $250,000 to a pla | [Link](https://longbridge.com/zh-CN/news/275986663.md) |
| 5,056 Shares in Johnson & Johnson $JNJ Acquired by Uniting Wealth Partners LLC | Uniting Wealth Partners LLC acquired 5,056 shares of Johnson & Johnson (NYSE: JNJ) in Q3, valued at approximately $938,0 | [Link](https://longbridge.com/zh-CN/news/276006840.md) |
| Protagonist Therapeutics (PTGX) to Release Earnings on Friday | Protagonist Therapeutics (NASDAQ:PTGX) is set to release its Q4 2025 earnings on February 20, with analysts expecting a  | [Link](https://longbridge.com/zh-CN/news/275855554.md) |
| Pennsylvania jury finds Johnson & Johnson liable for cancer in latest talc trial | A Pennsylvania jury awarded $250,000 to the family of Gayle Emerson, who claimed Johnson & Johnson's talc-based baby pow | [Link](https://longbridge.com/zh-CN/news/275939086.md) |
| Assenagon Asset Management S.A. Decreases Stock Holdings in Protagonist Therapeutics, Inc. $PTGX | Assenagon Asset Management S.A. reduced its stake in Protagonist Therapeutics, Inc. by 28.4% in Q3, owning 65,756 shares | [Link](https://longbridge.com/zh-CN/news/270461220.md) |

---

> **免责声明**：本文内容仅供参考，不构成任何投资建议。